Cardiovascular management of septic shock.
暂无分享,去创建一个
[1] D. Cook,et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. , 1995, Critical care medicine.
[2] H P Greisler,et al. Noninvasive cardiac monitoring. , 1987, The Nursing clinics of North America.
[3] W. Schumer. Steroids in the Treatment of Clinical Septic Shock , 1976, Annals of surgery.
[4] P. Bollaert,et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. , 1998, Critical care medicine.
[5] J. Cohen. Practical implications of the availability of effective drugs to treat sepsis. , 2001, Current opinion in critical care.
[6] G. Schierhout,et al. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials , 1998, BMJ.
[7] G. Majno. The ancient riddle of sigma eta psi iota sigma (sepsis). , 1991, The Journal of infectious diseases.
[8] G. Schmidt,et al. Sodium bicarbonate for the treatment of lactic acidosis. , 2000, Chest.
[9] M. Haller,et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. , 1999, Critical care medicine.
[10] J. Siegel,et al. Arteriovenous shunting in high cardiac output shcok syndromes. , 1968, Surgery, gynecology & obstetrics.
[11] C. Sprung,et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. , 1984, The New England journal of medicine.
[12] L. Papazian,et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? , 1992, Chest.
[13] J. Takala,et al. Regional blood flow and oxygen transport in septic shock , 1993, Critical care medicine.
[14] R. Bellomo,et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis , 2002, Critical care medicine.
[15] L. Goldman,et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, JAMA.
[16] D. Kuhl. Current strategies for managing the patient with sepsis. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[17] E. Ivers,et al. Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .
[18] D. Landry,et al. The pathogenesis of vasodilatory shock. , 2001, The New England journal of medicine.
[19] M. Oz,et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. , 1997, Circulation.
[20] S. Opal,et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.
[21] F Baisch,et al. Noninvasive cardiac output measurement by arterial pulse analysis compared with inert gas rebreathing. , 1993, Journal of applied physiology.
[22] B. Wiggs,et al. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. , 1990, Annals of internal medicine.
[23] M. Weil,et al. SHOCK CAUSED BY GRAM-NEGATIVE MICROORGANISMS. ANALYSIS OF 169 CASES. , 1964, Annals of internal medicine.
[24] C. Sessler,et al. New concepts in sepsis , 2002, Current opinion in critical care.
[25] G. Clermont,et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.
[26] R. Bellomo,et al. Pro/con clinical debate: Is high-volume hemofiltration beneficial in the treatment of septic shock? , 2002, Critical care.
[27] L. Lasagna,et al. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. , 1956, Bulletin of the Johns Hopkins Hospital.
[28] E. Rivers,et al. Early goal-directed therapy prevents organ failure and mortality in severe sepsis and septic shock , 2003 .
[29] M. Welte,et al. N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: Results of a prospective, randomized, double-blind study , 2000, Critical care medicine.
[30] J. Vincent,et al. Has the mortality of septic shock changed with time. , 1998, Critical care medicine.
[31] K. Laupland,et al. Utility of esophageal Doppler as a minimally invasive hemodynamic monitor: a review , 2002, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[32] A. Wu. Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression? , 2001, Intensive Care Medicine.
[33] E. Bennett,et al. A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. , 1993, JAMA.
[34] P. Nabet,et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study , 1997, Intensive Care Medicine.
[35] J. Siegel. Assessing the use of activated protein C in the treatment of severe sepsis. , 2002, The New England journal of medicine.
[36] G. Guyatt,et al. Colloid Use for Fluid Resuscitation: Evidence and Spin , 2001, Annals of Internal Medicine.
[37] R. Lyons. The effects of high-dose corticosteroids in patients with septic shock , 1985 .
[38] C. Perret,et al. Pulmonary artery catheter: does the problem lie in the users? , 2002, Chest.
[39] R. Nunnally,et al. Carbicarb, sodium bicarbonate, and sodium chloride in hypoxic lactic acidosis. Effect on arterial blood gases, lactate concentrations, hemodynamic variables, and myocardial intracellular pH. , 1993, Chest.
[40] J. Morris,et al. Adrenal hemorrhage: a 25-year experience at the Mayo Clinic. , 2001, Mayo Clinic proceedings.
[41] Hypercarbic acidosis reduces cardiac resuscitability , 1991, Critical care medicine.
[42] R. C. Dennis,et al. Myocardial depression during sepsis. , 1977, American journal of surgery.
[43] J. Bakker,et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock* , 2004, Critical care medicine.
[44] D. Mathieu,et al. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: A prospective, controlled clinical study , 1991, Critical care medicine.
[45] R. Postier,et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study , 2001, Critical care medicine.
[46] F. Kern,et al. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies , 2001, Intensive Care Medicine.
[47] J. Shapiro. Functional and metabolic responses of isolated hearts to acidosis: effects of sodium bicarbonate and Carbicarb. , 1990, The American journal of physiology.
[48] S. Pastores,et al. Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. , 1996, The American journal of gastroenterology.
[49] S. Nasraway,et al. Normal lactate/pyruvate ratio during overwhelming polymicrobial bacteremia and multiple organ failure. , 1994, Anesthesiology.
[50] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock , 2003, Current infectious disease reports.
[51] Richard F. Davis,et al. "Normothermic range" temperature affects myocardial infarct size. , 1994, Cardiovascular research.
[52] K. Walley,et al. Physiology of vasopressin relevant to management of septic shock. , 2001, Chest.
[53] N. Maassen,et al. Evaluation of noninvasive determinants for capillary leakage syndrome in septic shock patients , 2000, Intensive Care Medicine.
[54] R. Dellinger. Current therapy for sepsis. , 1999, Infectious disease clinics of North America.
[55] J. A. Kruse,et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.
[56] G. Camussi,et al. Hemofiltration reduces the serum priming activity on neutrophil chemiluminescence in septic patients. , 2001, Kidney international.
[57] D. Frommer. The effects of high-dose corticosteroids in patients with septic shock: Sprung CL, Caralis PV, Marcial EH, et al N Engl J Med 311:1137–1143 Nov 1984 , 1985 .
[58] L. Kinsell,et al. THE USE OF CORTICOIDS IN ASSOCIATION WITH ANTIBIOTICS IN THE MANAGEMENT OF UNUSUALLY SEVERE INFECTIONS , 1955, Annals of the New York Academy of Sciences.
[59] M. Weil,et al. The Shock Syndrome Associated with Bacteremia Due to Gram-Negative Bacilli , 1958 .
[60] G. Meduri. An Historical Review of Glucocorticoid Treatment in Sepsis. Disease Pathophysiology and the Design of Treatment Investigation , 1999 .
[61] M. Fink. Cytopathic hypoxia. Is oxygen use impaired in sepsis as a result of an acquired intrinsic derangement in cellular respiration? , 2002, Critical care clinics.
[62] J. Hibbert,et al. Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. , 1996, Annals of surgery.
[63] L. U. G. Attinoni,et al. A TRIAL OF GOAL-ORIENTED HEMODYNAMIC THERAPY IN CRITICALLY ILL PATIENTS , 2000 .
[64] A. Groeneveld,et al. Peripheral vascular resistance in septic shock: its relation to outcome , 2004, Intensive Care Medicine.
[65] J. W. Henry,et al. Fever in acute pulmonary embolism. , 2000, Chest.
[66] X Viviand,et al. Effect of norepinephrine on the outcome of septic shock , 2000, Critical care medicine.
[67] Rinaldo Bellomo,et al. A pilot study of coupled plasma filtration with adsorption in septic shock* , 2002, Critical care medicine.
[68] K. Demirel,et al. Fever in pulmonary embolism , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[69] M. C. Townsend,et al. Experience with phenylephrine as a component of the pharmacologie support of septic shock , 1991, Critical care medicine.
[70] D. Pittet,et al. Impact of immunomodulating therapy on morbidity in patients with severe sepsis. , 1999, American journal of respiratory and critical care medicine.
[71] F. Gouin,et al. Renal effects of norepinephrine used to treat septic shock patients. , 1990, Critical care medicine.
[72] W. Knaus,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.
[73] G. Majno,et al. The ancient riddle of σηψιζ (sepsis) , 1991 .
[74] P. Crone,et al. Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study. , 1994, Critical care medicine.
[75] R. Alcázar,et al. Silent transmural myocardial ischemia during septic shock in a patient with normal coronary arteries , 2001, Intensive Care Medicine.
[76] R. Bellomo,et al. High-volume haemofiltration in human septic shock , 2001, Intensive Care Medicine.
[77] K. Werdan,et al. Intravenous immunoglobulin for prophylaxis and therapy of sepsis. , 2001, Current opinion in critical care.
[78] W. Shoemaker,et al. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. , 1988, Chest.
[79] A. Wechsler-Fördös,et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states , 2005, Intensive Care Medicine.
[80] M. Oz,et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. , 1999, Circulation.
[81] R. Townsend,et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. , 1999, The Journal of trauma.
[82] R. Wenzel. Treating sepsis. , 2002, The New England journal of medicine.
[83] Cam Donaldson,et al. An economic evaluation of activated protein C treatment for severe sepsis. , 2002, The New England journal of medicine.
[84] M. Pinaud,et al. Norepinephrine therapy has no deleterious renal effects in human septic shock. , 1989, Critical care medicine.
[85] B. Altura. Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal. , 1975, The Journal of pharmacology and experimental therapeutics.
[86] M. Haupt,et al. Impact of critical care physician staffing on patients with septic shock in a university hospital medical intensive care unit. , 1988, JAMA.
[87] S. Opal,et al. High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial , 2001 .
[88] S. Berger,et al. Clinical trial design in studies of corticosteroids for bacterial infections. , 1974, Annals of internal medicine.
[89] J P Archie,et al. Mathematic Coupling of Data: A Common Source of Error , 1981, Annals of surgery.
[90] C. Esmon,et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. , 2001, The New England journal of medicine.
[91] E. Rackow,et al. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. , 1992, Chest.
[92] J. Edwards,et al. Reversal of intractable septic shock with norepinephrine therapy. , 1988, Critical care medicine.
[93] J. E. Cassidy. Therapy in collapse due to meningococcus infection. , 1957, Annals of internal medicine.
[94] M. Weil,et al. HEMODYNAMIC AND METABOLIC STUDIES ON SHOCK ASSOCIATED WITH GRAM NEGATIVE BACTEREMIA , 1973, Medicine.
[95] R. Bersin,et al. A Controlled Clinical Trial of Dichloroacetate for Treatment of Lactic Acidosis in Adults , 1992 .
[96] F. Ognibene,et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. , 1990, Annals of internal medicine.
[97] T. Butler,et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients , 2001, Critical care medicine.
[98] A. Jensen,et al. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. , 2002, Archives of internal medicine.
[99] J. Vincent,et al. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. , 1999, Critical care medicine.
[100] A. Weyland,et al. Comparison of cardiac output assessed by pulse-contour analysis and thermodilution in patients undergoing minimally invasive direct coronary artery bypass grafting. , 1999, Journal of cardiothoracic and vascular anesthesia.
[101] Véronique Sébille,et al. Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock , 2002 .
[102] T. Clemmer,et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.
[103] M. Fink,et al. Cytopathic Hypoxia in Sepsis: An Overview , 1999 .
[104] P. Marik,et al. The hemodynamic derangements in sepsis: implications for treatment strategies. , 1998, Chest.
[105] M. Dünser,et al. The Effects of Vasopressin on Systemic Hemodynamics in Catecholamine-Resistant Septic and Postcardiotomy Shock: A Retrospective Analysis , 2001, Anesthesia and analgesia.
[106] G. Van den Berghe,et al. Anterior pituitary function during critical illness and dopamine treatment. , 1996, Critical care medicine.
[107] I. Mackenzie. The haemodynamics of human septic shock * , 2001, Anaesthesia.
[108] B. Stegmayr,et al. Plasmapheresis in severe sepsis or septic shock. , 1996, Blood purification.
[109] J. De Sutter,et al. Cytokine removal during continuous hemofiltration in septic patients. , 1999, Journal of the American Society of Nephrology : JASN.
[110] R. Dellinger,et al. Pharmacologic issues in the management of septic shock. , 2000, Critical care clinics.
[111] H. S. Warren,et al. Risks and benefits of activated protein C treatment for severe sepsis. , 2002, The New England journal of medicine.
[112] R. Hotchkiss,et al. Reevaluation of the role of cellular hypoxia and bioenergetic failure in sepsis. , 1992, JAMA.
[113] P. Marik,et al. Adrenal insufficiency in the critically ill: a new look at an old problem. , 2002, Chest.
[114] S. Kleinman,et al. A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care , 1999 .
[115] R. Lefering,et al. Steroid controversy in sepsis and septic shock: a meta-analysis. , 1995, Critical care medicine.
[116] G. Gallioli,et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. , 1998, Intensive care medicine.
[117] A. Feydy,et al. Depletion of neurohypophyseal content of vasopressin in septic shock. , 2002, Critical care medicine.
[118] K. Reinhart,et al. Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. , 1995, Critical care medicine.
[119] D. Cook,et al. Crystalloids vs. colloids in fluid resuscitation: a systematic review. , 1999, Critical care medicine.
[120] T. Fehr,et al. Elevation of troponin I in sepsis and septic shock , 2001, Intensive Care Medicine.
[121] J. Shelhamer,et al. Profound but reversible myocardial depression in patients with septic shock. , 1984, Annals of internal medicine.
[122] John C. Chaney,et al. Minimally invasive hemodynamic monitoring for the intensivist: Current and emerging technology , 2002, Critical care medicine.
[123] M. Llewelyn,et al. New insights into the pathogenesis and therapy of sepsis and septic shock. , 2001, Current clinical topics in infectious diseases.
[124] D. Annane,et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. , 2000, JAMA.
[125] J. Vincent,et al. Early hemodynamic course of septic shock. , 1995, Critical care medicine.
[126] J. Vincent,et al. Myocardial depression characterizes the fatal course of septic shock. , 1992, Surgery.
[127] William A. Knaus,et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, Journal of the American Medical Association (JAMA).
[128] R. Busund,et al. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial , 2002, Intensive Care Medicine.
[129] C. Hinds,et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. , 1994, The New England journal of medicine.
[130] W. Shoemaker,et al. Sequence of physiologic patterns in surgical septic shock , 1993, Critical care medicine.
[131] L. Goldman,et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, JAMA.
[132] T. Nakanishi,et al. Influence of acidosis on inotropic effect of catecholamines in newborn rabbit hearts. , 1987, The American journal of physiology.
[133] C. Chopin,et al. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. , 1993, Chest.
[134] D. Berman,et al. Left ventricular performance in septic shock: reversible segmental and global abnormalities. , 1985, American heart journal.
[135] I. Reid,et al. Role of vasopressin deficiency in the vasodilation of septic shock. , 1997, Circulation.
[136] M. Haupt,et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. , 1983, Critical care medicine.
[137] Cornelius Weiller,et al. Dysfunction of vasomotor reactivity in severe sepsis and septic shock , 2001, Intensive Care Medicine.
[138] S. Nasraway,et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock , 1998, The Lancet.
[139] Maximilians-Universitat Munchen. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study , 2005 .
[140] T. Evans,et al. EMERGING THERAPIES IN SEVERE SEPSIS , 2002, Thorax.
[141] E. Rackow,et al. Effects of perfusion pressure on tissue perfusion in septic shock , 2000, Critical care medicine.
[142] Yoshiki Mori,et al. A validation study of aortic stroke volume using dynamic 4-dimensional color Doppler: an in vivo study. , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[143] P. Poole‐Wilson,et al. Effect of pH on ionic exchange and function in rat and rabbit myocardium. , 1975, The American journal of physiology.
[144] C. Ince,et al. Microcirculatory oxygenation and shunting in sepsis and shock. , 1999, Critical care medicine.
[145] J Ean,et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.